Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biochemistry ; 49(33): 7108-18, 2010 Aug 24.
Artigo em Inglês | MEDLINE | ID: mdl-20583779

RESUMO

Polyglutamine expansion in the exon 1 domain of huntingtin leads to aggregation into beta-sheet-rich insoluble aggregates associated with Huntington's disease. We assessed eight polyglutamine peptides with different permutations of N-methylation of backbone and side chain amides as potential inhibitors of polyglutamine aggregation. Surprisingly, the most effective inhibitor, 5QMe(2) [Anth-K-Q-Q(Me(2))-Q-Q(Me(2))-Q-CONH(2), where Anth is N-methylanthranilic acid and Q(Me(2)) is side chain N-methyl Q], has only side chain methylations at alternate residues, highlighting the importance of side chain interactions in polyglutamine fibrillogenesis. Above a 1:1 stoichiometric ratio, 5QMe(2) can completely prevent fibrillation of a synthetic aggregating peptide, YAQ(12)A; it also shows significant inhibition at substoichiometric ratios. Surface plasmon resonance (SPR) measurements show a moderate K(d) with very fast k(on) and k(off) values. Sedimentation equilibrium analytical ultracentrifugation indicates that 5QMe(2) is predominantly or entirely monomeric at concentrations of

Assuntos
Peptídeos/química , Peptídeos/farmacologia , Humanos , Doença de Huntington/metabolismo , Metilação , Peptídeos/antagonistas & inibidores , Peptídeos/metabolismo , Estrutura Secundária de Proteína , Ressonância de Plasmônio de Superfície
2.
Biophys J ; 97(8): 2295-305, 2009 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-19843462

RESUMO

PolyQ peptides teeter between polyproline II (PPII) and beta-sheet conformations. In tandem polyQ-polyP peptides, the polyP segment tips the balance toward PPII, increasing the threshold number of Gln residues needed for fibrillation. To investigate the mechanism of cis-inhibition by flanking polyP segments on polyQ fibrillation, we examined short polyQ, polyP, and tandem polyQ-polyP peptides. These polyQ peptides have only three glutamines and cannot form beta-sheet fibrils. We demonstrate that polyQ-polyP peptides form small, soluble oligomers at high concentrations (as shown by size exclusion chromatography and diffusion coefficient measurements) with PPII structure (as shown by circular dichroism spectroscopy and (3)J(HN-C alpha) constants of Gln residues from constant time correlation spectroscopy NMR). Nuclear Overhauser effect spectroscopy and molecular modeling suggest that self-association of these peptides occurs as a result of both hydrophobic and steric effects. Pro side chains present three methylenes to solvent, favoring self-association of polyP through the hydrophobic effect. Gln side chains, with two methylene groups, can adopt a conformation similar to that of Pro side chains, also permitting self-association through the hydrophobic effect. Furthermore, steric clashes between Gln and Pro side chains to the C-terminal side of the polyQ segment favor adoption of the PPII-like structure in the polyQ segment. The conformational adaptability of the polyQ segment permits the cis-inhibitory effect of polyP segments on fibrillation by the polyQ segments in proteins such as huntingtin.


Assuntos
Interações Hidrofóbicas e Hidrofílicas , Peptídeos/química , Poliaminas/química , Multimerização Proteica , Cromatografia em Gel , Dicroísmo Circular , Difusão , Glutamina/química , Humanos , Proteína Huntingtina , Modelos Químicos , Modelos Moleculares , Proteínas do Tecido Nervoso/química , Ressonância Magnética Nuclear Biomolecular , Proteínas Nucleares/química , Conformação Proteica , Estrutura Secundária de Proteína , Temperatura , Temperatura de Transição
3.
J Am Chem Soc ; 128(36): 11906-15, 2006 Sep 13.
Artigo em Inglês | MEDLINE | ID: mdl-16953631

RESUMO

QS-21 is one of the most promising new adjuvants for immune response potentiation and dose-sparing in vaccine therapy given its exceedingly high level of potency and its favorable toxicity profile. Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a critical adjuvant component for immune response augmentation. QS-21 is a natural product immunostimulatory adjuvant, eliciting both T-cell- and antibody-mediated immune responses with microgram doses. Herein is reported the synthesis of QS-21A(api) in a highly modular strategy, applying novel glycosylation methodologies to a convergent construction of the potent saponin immunostimulant. The chemical synthesis of QS-21 offers unique opportunities to probe its mode of biological action through the preparation of otherwise unattainable nonnatural saponin analogues.


Assuntos
Adjuvantes Imunológicos/síntese química , Quillaja/química , Saponinas/síntese química , Adjuvantes Imunológicos/química , Sequência de Carboidratos , Dados de Sequência Molecular , Ácido Oleanólico/análogos & derivados , Ácido Oleanólico/química , Quillaja/imunologia , Sapogeninas/química , Saponinas/química , Trissacarídeos/síntese química , Trissacarídeos/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...